HopeStage
Back to all studies
Enrolling By InvitationNCT03338387

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

Medication studyAges 18–30Eating disorders
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 30 years.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 6, 2003
Recruitment status
Enrolling By Invitation
Enrollment listed in the registry
24
Sponsor
Charles University, Czech Republic
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Not clearly listed
Age range
From 18 Years to 30 Years
Official registry ID
NCT03338387
Official title
Show the full official title

Acipimox Administration Together With Short-Term Exercise Exerts A Co-Feedback of Growth Hormone, Pancreatic Polypeptide, Peptide YY and Leptin on Ghrelin in Young Bulimic Czech Women: A Randomized Study

Recruitment & locations

By invitation

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Charles University, Czech Republic, a university.

Does this study involve medication?

Yes. The study involves medication, including Acipimox and Placebo.

Who can participate?

Listed age limits: 18 years to 30 years.

Is this study still recruiting?

The registry lists this study as enrolling by invitation.

Want to explore more studies?

Explore studies